Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
Rita Ribeiro, Maria João Carvalho, João Gonçalves, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type
Md Abdus Subhan, Farzana Parveen, Hassan Shah, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2204-2204
Open Access | Times Cited: 49
Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer
Sawsan Sudqi Said, Wisam Nabeel Ibrahim
Biomedicines (2024) Vol. 12, Iss. 2, pp. 369-369
Open Access | Times Cited: 8
Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer
Jasmin Linh On, Sakineh Ghaderi, Carina Rittmann, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1078-1078
Open Access | Times Cited: 1
DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities
Wenyu Cai, Xiaoli Cai, Yi-ran Fei, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access | Times Cited: 1
Special Issue: Nanotherapeutics in Women's Health Emerging Nanotechnologies for Triple‐Negative Breast Cancer Treatment
Sofia Torres Quintas, Ana Manuela Canha Borges, Maria José Oliveira, et al.
Small (2023)
Open Access | Times Cited: 20
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer
Pénélope Desroys du Roure, Laurie Lajoie, Aude Mallavialle, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e007135-e007135
Open Access | Times Cited: 5
Cancer‐Derived Extracellular Vesicle ITGB2 Promotes the Progression of Triple‐Negative Breast Cancer via the Activation of Cancer‐Associated Fibroblasts
Jingjing Fan, Tong Sha, Binlin Ma
Global Challenges (2025) Vol. 9, Iss. 3
Open Access
Intrinsic Subtype and Immunity Score in identification of Triple-Negative Breast Cancer at Low Risk
Xinyu Ren, Tong Zhou, Yu Song, et al.
The Breast (2025), pp. 103889-103889
Open Access
Novel Strategy of Antibody Affinity Maturation and Enhancement of Nucleolin‐Mediated Antibody‐Dependent Cellular Cytotoxicity Against Triple‐Negative Breast Cancer
Rita Ribeiro, Jorge M. B. Vítor, Anastasiya Voronovska, et al.
Biotechnology Journal (2025) Vol. 20, Iss. 1
Closed Access
Breast cancer and its genetic heterogeneity at single cell level: A concise perspective of cellular architecture and taxonomy
Riya Sharma, Neha Parihar, Keerti Gopi, et al.
Elsevier eBooks (2025), pp. 89-112
Closed Access
Mapping molecular landscapes in triple-negative breast cancer: insights from spatial transcriptomics
Fares Saeed H. Al-Mansour, Hassan H. Almasoudi, Ali Albarrati
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Monoclonal Antibodies in Clinical Trials for Breast Cancer Treatment
Rahaman Shaik, V. Pavani Sai Mounika, S. Begum, et al.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2025)
Closed Access
Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma
Ghazaal Roozitalab, Behnaz Abedi, Saber İmani, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 3, pp. 889-918
Closed Access | Times Cited: 4
Extracellular vesicles in triple-negative breast cancer: current updates, challenges and future prospects
Prashant Tiwari, Anis Ahmad Chaudhary, Saurabh Gupta, et al.
Frontiers in Molecular Biosciences (2025) Vol. 12
Open Access
Ribonuclease 1 Enhances Antitumor Immunity against Breast Cancer by Boosting T cell Activation
Ying‐Nai Wang, Heng‐Huan Lee, Zhou Jiang, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 10, pp. 2957-2973
Open Access | Times Cited: 10
Tertiary Lymphoid Structures (TLSs) and Stromal Blood Vessels Have Significant and Heterogeneous Impact on Recurrence, Lymphovascular and Perineural Invasion amongst Breast Cancer Molecular Subtypes
ALINA CRISTINA BARB, Mihaela Pasca Fenesan, Marilena Pirtea, et al.
Cells (2023) Vol. 12, Iss. 8, pp. 1176-1176
Open Access | Times Cited: 9
Engineering a facile and versatile nanoplatform to facilitate the delivery of multiple agents for targeted breast cancer chemo-immunotherapy
Amirhossein Bahreyni, Yasir Mohamud, Jingchun Zhang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 163, pp. 114789-114789
Open Access | Times Cited: 9
A real‐world study of immune checkpoint inhibitors in advanced triple‐negative breast cancer
Zheng Zhang, Yadi Zhang, Chuanling Liu, et al.
Cancer Innovation (2023) Vol. 2, Iss. 3, pp. 172-180
Open Access | Times Cited: 7
Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes in vitro
Maxim Olsson, Peter Larsson, Junko Johansson, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 7
Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response
Andrea Aran, Gonzalo Lázaro, V. Marco, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis
Qi Xu, Xiaoyu Feng, Siyuan Qin, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Characterizing the Inflammatory Profile of Neutrophil-Rich Triple-Negative Breast Cancer
Fatma Alqutami, Walaa AlHalabi, Aswathy Vijayakumar, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 747-747
Open Access | Times Cited: 1
Combination Nano-Delivery Systems Remodel the Immunosuppressive Tumor Microenvironment for Metastatic Triple-Negative Breast Cancer Therapy
Liya Bai, Hui Liu, Ran You, et al.
Molecular Pharmaceutics (2024) Vol. 21, Iss. 5, pp. 2148-2162
Closed Access | Times Cited: 1
Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models
Robbe Salembier, Caro De Haes, Julie Bellemans, et al.
Breast Cancer Research (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 1
Precision prognostication in breast cancer: unveiling a long non-coding RNA-based model linked to disulfidptosis for tailored immunotherapeutic strategies
Cheng‐Lu Jiang, Shengke Zhang, Lai Jiang, et al.
Aging (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top